Makell Murphy
Surgical · Long Beach, CANPI 1255621694
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 354 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Among surgical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 354 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$1K
- Integra Lifesciences Corporation$1K
- Medtronic$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$941
- Alkermes, Inc.$625
- Otsuka America Pharmaceutical, Inc.$556
- plus $2K from 15 others
What the payments were for
- Food & beverage$7,840100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 84 | $1,486 |
| Integra Lifesciences Corporation | 38 | $1,165 |
| Medtronic | 34 | $1,092 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $941 |
| Alkermes, Inc. | 32 | $625 |
| Otsuka America Pharmaceutical, Inc. | 17 | $556 |
| AbbVie | 25 | $380 |
| Lundbeck LLC | 19 | $346 |
| Neurocrine Biosciences, Inc. | 9 | $256 |
| Bayer | 11 | $215 |
| Johnson & Johnson | 7 | $172 |
| Gilead | 5 | $118 |
| E.r. Squibb & Sons, L.L.C. | 6 | $106 |
| Amgen | 4 | $84 |
| Teva Pharmaceuticals USA, Inc. | 3 | $79 |
| Lilly USA, LLC | 2 | $57 |
| Novo Nordisk | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Almatica Pharma LLC | 2 | $30 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$242
- INTELLIS ADAPTIVESTIM$137
- Fanapt$118
How this compares
$7,840 in reported general payments places this provider in the 95th percentile of 729 surgical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 97 | $58,744 |
| FarxigaDapagliflozin Propanediol | 38 | $22,445 |
| CaplytaLumateperone Tosylate | 11 | $17,166 |
| FanaptIloperidone | 13 | $14,434 |
| JardianceEmpagliflozin | 19 | $12,959 |
| RybelsusSemaglutide | 13 | $11,869 |
| TrulicityDulaglutide | 12 | $11,228 |
| KerendiaFinerenone | 16 | $9,786 |
| EliquisApixaban | 16 | $8,398 |
| Diclofenac Sodium | 12 | $6,511 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $6,035 |
| VascepaIcosapent Ethyl | 16 | $4,381 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 108 | $4,374 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $4,045 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $3,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $941 | $17,16611 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,486 | $14,43413 claims |
| Novo NordiskRybelsus | $50 | $11,86913 claims |
| Lilly USA, LLCTrulicity | $57 | $11,22812 claims |
| BayerKerendia | $215 | $9,78616 claims |
| Almatica Pharma LLCSertraline Hcl | $30 | $839264 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 surgical providers in California.
Other surgical in Long Beach
- Crystal Rene de CotretLong Beach$15K
- Lauren AmicoVista$989K
- Cheyanne MallasWest Hollywood$199K
- Laura PietrzakMarina del Rey$63K
- Jane HartiganSanta Rosa$27K
- Kenny NgoPalo Alto$25K
- Crispin MarRancho Santa Margarita$23K
- Robert FrostRancho Santa Margarita$22K
- Audie LeeSan Francisco$21K
- Gregory BrunetSanta Barbara$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.